Blood Purification Studies in the ICU: What Endpoints Should We Use?

被引:4
|
作者
Forni, Lui G. [1 ,2 ,3 ]
机构
[1] Royal Surrey Hosp, Dept Crit Care, Guildford, Surrey, England
[2] Royal Surrey Hosp, SPACeR Grp, Surrey Perioperat Anaesthesia & Crit Care Collabo, Guildford, Surrey, England
[3] Univ Surrey, Fac Hlth Sci, Dept Clin & Expt Med, Guildford, Surrey, England
关键词
Acute kidney injury; Kidney replacement therapy; Blood purification techniques; Randomized controlled trials; Heterogeneity of treatment effect; Trial sequential analysis; POLYMYXIN-B HEMOPERFUSION; CLINICAL-TRIALS; SEPTIC SHOCK; SEPSIS; MORTALITY; CARE; PREDICTION; MEDICINE; PATIENT; ARDS;
D O I
10.1159/000523761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The potential for treatment of the critically ill using blood purification techniques has been discussed for several decades. However, since the first attempts at applying extracorporeal techniques to patients with sepsis were described, there has been considerable hesitancy towards the widespread adoption of such methods, given the lack of mortality benefit observed and indeed the paucity of randomized controlled studies. However, this is not unique so far as studies on the critically ill are concerned where there is a dearth of studies providing a positive finding to influence clinical practice. Consequently, as well as targeted patient selection, it is perhaps time to consider endpoints other than mortality in studies on the critically ill, particularly in blood purification studies where, to-date, such heterogeneous groups of patients have been studied.
引用
收藏
页码:990 / 996
页数:7
相关论文
共 50 条
  • [21] Treatment of Delirium in Older Persons: What We Should Not Do!
    Lauretani, Fulvio
    Bellelli, Giuseppe
    Pela, Giovanna
    Morganti, Simonetta
    Tagliaferri, Sara
    Maggio, Marcello
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [22] Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address
    Caminati, Marco
    Senna, Gianenrico
    Guerriero, Massimo
    Darna, Anna Rita
    Chieco-Bianchi, Fulvia
    Stefanizzi, Giorgia
    Montagni, Marcello
    Ridolo, Erminia
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 31 : 28 - 35
  • [23] Renal replacement therapy in the ICU: when should we STARRT?
    Bellomo, Rinaldo
    CRITICAL CARE AND RESUSCITATION, 2019, 21 (03) : 156 - 157
  • [24] How soon should we start interventional feeding in the ICU?
    Fremont, Richard D.
    Rice, Todd W.
    CURRENT OPINION IN GASTROENTEROLOGY, 2014, 30 (02) : 178 - 181
  • [25] Intensive care: what should we measure?
    Laake, Jon Henrik
    Hofso, Kristin
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (08) : 709 - 709
  • [26] One minute to assess frailty, but what should we do next?
    Richardson, K.
    Hopker, J.
    ANAESTHESIA, 2016, 71 (06) : 622 - 626
  • [27] What should we expect from psychotherapy?
    Goldfried, Marvin R.
    CLINICAL PSYCHOLOGY REVIEW, 2013, 33 (07) : 862 - 869
  • [28] What every intensivist should know about: Trust in the ICU
    Kazi, Abdul W.
    Yoo, Erika J.
    Oxman, David
    JOURNAL OF CRITICAL CARE, 2024, 83
  • [29] Alzheimer's Disease Costs: What We Know and What We Should Take into Account
    Colucci, Luisa
    Bosco, Massimiliano
    Fasanaro, Angiola Maria
    Gaeta, Giuseppe Lucio
    Ricci, Giovanna
    Amenta, Francesco
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (04) : 1311 - 1324
  • [30] Curcumin for monoclonal gammopathies. What can we hope for, what should we fear?
    Vermorken, A. J. M.
    Zhu, J.
    Van de Ven, W. J. M.
    Andres, E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (03) : 350 - 360